David Einhorn
Greenlight Capital
David Einhorn The Medicines Company stake
total: 357
Greenlight Capital MDCO trades
- Total transactions:
- 5
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 3
- Held since:
- 2017 Q4
- Held for:
- 9 quarters
- Latest activity:
- 2020 Q1
According to 2026 Q2 report, David Einhorn doesn't hold any The Medicines Company (MDCO) shares. To date, the estimated cost basis is nearly $27.34 for "buy" trades and estimated average "sell" price is $71.6. Greenlight Capital first purchased MDCO in 2017 Q4, initially acquiring 1,000,000 shares. Since the initial investment in The Medicines Company (MDCO), Greenlight Capital has made 4 more transactions.
When did David Einhorn sell The Medicines Company (MDCO)?
David Einhorn sold off the entire The Medicines Company (MDCO) position in 2020 Q1.
When did David Einhorn buy The Medicines Company (MDCO)?
David Einhorn first invested in The Medicines Company (MDCO) in 2017 Q4 at the reported quarter-end price of $27.34 per share.
What's the cost basis of Greenlight Capital's MDCO stake?
The estimated cost basis for The Medicines Company (MDCO) stake is around $27.34 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $27.34
- Weighted AVG sell price:
- $71.60
David Einhorn's historical trades in The Medicines Company
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2020 Q1
|
0.00%
|
$84.94
|
-100% (-229,900)
|
|||
|
2019 Q4
|
1.45%
|
$84.94
|
-68.58% (-501,700)
|
|||
|
2019 Q2
|
1.97%
|
$36.47
|
-22.89% (-217,200)
|
|||
|
2018 Q3
|
1.20%
|
$29.91
|
-5.12% (-51,200)
|
|||
|
2017 Q4
|
0.50%
|
$27.34
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.